Atopic dermatitis is a chronic or chronic-recurrent, non-contagious skin disease, affecting 70 million people in China alone and about 47 million people in the US, Japan and the EU.
Although non-lethal, atopic dermatitis and its symptoms, especially eczema, unbearable itching and infections of the skin, impact mental health and are associated with parental depression, antidepressant use and suicidality.
Approximately 70% of all people affected by atopic dermatitis have a colonization with Staphylococcus aureus disbalancing the microbiome and causing severe symptoms.*
*Kong, H.H et al. Genome Res (2015)
Artilysin® is the solution
We designed an Artilysin® that will revolutionize the global atopic dermatitis treatment market by specifically eliminating S. aureus.
Artilysin®s are profiting from the fast mode of action, the high specificity, a high safety profile and a high resistance stability. Further, the main focus in the development of this Artilysin® lies on balancing the skin microbiome by eliminating only the pathogen S. aureus whilst leaving the commensal microorganisms intact. This secures a healthy skin microbiome.
Artilysin®s are predestined to reshape the atopic dermatitis market.